Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inflammatory Breast Neoplasms Clear all
Not listed Not applicable Interventional

UCLA Breast Cancer Survivor Health Promotion Research Study

NCT05113485
View directory record Official record
Conditions
Breast Cancer
Interventions
Diabetes Prevention Program-based lifestyle change intervention (DPP), Highly Microbiota-Accessible Foods (HMAFs) intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer

NCT00343512
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, protein expression analysis, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy
Drug · Genetic · Other + 1 more
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 26, 2012 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

NCT00038402
View directory record Official record
Conditions
Breast Cancer
Interventions
Herceptin, Taxol, Fluorouracil, Cytoxan, Epirubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 1 Interventional

Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

NCT00002616
View directory record Official record
Conditions
Breast Cancer
Interventions
aldesleukin, filgrastim, carboplatin, cyclophosphamide, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
Up to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer

NCT00016549
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

NCT01938833
View directory record Official record
Conditions
HER2-negative Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
Romidepsin, Abraxane
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Not applicable Interventional

Hypnosis in Treating Hot Flashes in Breast Cancer Survivors

NCT00094133
View directory record Official record
Conditions
Breast Cancer, Cancer Survivor, Hot Flashes
Interventions
hot flashes attenuation, hypnotherapy
Procedure
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

NCT00003042
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, cisplatin, cyclophosphamide, doxorubicin hydrochloride, melphalan, mesna, paclitaxel, tamoxifen citrate, bone marrow ablation with stem cell support, conventional surgery, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Not applicable Interventional

Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer

NCT01755130
View directory record Official record
Conditions
Breast Neoplasm, Inflammatory Breast Carcinoma
Interventions
Photoacoustic Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
20 Years to 85 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 1Phase 2 Interventional

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

NCT00002627
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

NCT04215146
View directory record Official record
Conditions
Breast Cancer Metastatic
Interventions
Paclitaxel, Pelareorep, Avelumab
Drug · Biological
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
18
States / cities
Miami, Florida • Urbana, Illinois • Indianapolis, Indiana + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 2 Interventional

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

NCT03202316
View directory record Official record
Conditions
Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
Interventions
Atezolizumab, Cobimetinib, Eribulin, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

TKI258 for Metastatic Inflammatory Breast Cancer Patients

NCT01262027
View directory record Official record
Conditions
Breast Cancer
Interventions
Dovitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer

NCT00111787
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Paclitaxel
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Miami, Florida • Chicago, Illinois • Zion, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Veliparib With Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer

NCT01477489
View directory record Official record
Conditions
Breast Cancer
Interventions
Veliparib, Standard radiation treatment
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
19 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
5
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer

NCT00005822
View directory record Official record
Conditions
Breast Cancer
Interventions
doxorubicin hydrochloride, semaxanib, conventional surgery, radiation therapy, tamoxifen
Drug · Procedure · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Early Phase 1 Interventional Results available

Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer

NCT02415387
View directory record Official record
Conditions
Cognitive Side Effects of Cancer Therapy, Depression, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
typhoid vaccine, Placebo
Biological · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
35 Years to 80 Years · Female only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer

NCT00397761
View directory record Official record
Conditions
Breast Cancer
Interventions
capecitabine, paclitaxel albumin-stabilized nanoparticle formulation, neoadjuvant therapy
Drug · Procedure
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

NCT00513695
View directory record Official record
Conditions
Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
sunitinib malate, paclitaxel, doxorubicin hydrochloride, cyclophosphamide, filgrastim, therapeutic conventional surgery, laboratory biomarker analysis, flow cytometry
Drug · Biological · Procedure + 1 more
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
7
States / cities
Anchorage, Alaska • Tucson, Arizona • Boise, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test

NCT05243641
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Cancer
Interventions
Neratinib, Capmatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

MIRNA Profiling of Breast Cancer in Patients Undergoing Neoadjuvant or Adjuvant Treatment for Locally Advanced & Inflammatory Breast Cancer

NCT01231386
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer

NCT00001507
View directory record Official record
Conditions
Breast Neoplasm, Neoplasm Metastasis
Interventions
Monoclonal Antibody 3A1, Monoclonal Antibody 95-5-49, Monoclonal Antibody 95-6-22, Baxter Isolex 3001 Stem Cell Selection System, Ceprate SC
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional

Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

NCT00346229
View directory record Official record
Conditions
Breast Cancer
Interventions
filgrastim, pegfilgrastim, lyso-thermosensitive liposomal doxorubicin(Thermodox), hyperthermia treatment
Biological · Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer

NCT00118053
View directory record Official record
Conditions
Breast Cancer
Interventions
herceptin, carboplatin, docetaxel, conventional surgery, radiation therapy
Biological · Drug · Procedure
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
9
States / cities
East Brunswick, New Jersey • Freehold, New Jersey • Hamilton, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Sep 17, 2026, 5:15 AM EDT